News and Trends 11 Jun 2018
Danish Biotech Plans Phase II Study to Fight A Rare Eating Disorder
Saniona, a biotech focused on ion channel research, plans to test its lead candidate in a Phase IIa study for the rare eating disorder hypothalamic obesity. Saniona, based in Copenhagen, plans to start a Phase IIa trial testing its product, Tesomet, a combination of tesofensine and metoprolol, in hypothalamic obesity. The study would complement the […]